These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3197822)

  • 1. Prognostic factors in Hodgkin's disease stage IV.
    Specht L; Nissen NI
    Eur J Haematol; 1988 Oct; 41(4):359-67. PubMed ID: 3197822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hodgkin's disease and age.
    Specht L; Nissen NI
    Eur J Haematol; 1989 Aug; 43(2):127-35. PubMed ID: 2792320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden.
    Specht L; Nissen NI
    Eur J Haematol; 1988 Jul; 41(1):80-7. PubMed ID: 3402591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mantle irradiation alone for pathologic stage I and II Hodgkin's disease: long-term follow-up and patterns of failure.
    Liao Z; Ha CS; Vlachaki MT; Hagemeister F; Cabanillas F; Hess M; Tucker S; Cox JD
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(4):971-7. PubMed ID: 11429225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor burden as the most important prognostic factor in early stage Hodgkin's disease. Relations to other prognostic factors and implications for choice of treatment.
    Specht L; Nordentoft AM; Cold S; Clausen NT; Nissen NI
    Cancer; 1988 Apr; 61(8):1719-27. PubMed ID: 3349432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term outcome of treatment for Ann Arbor Stage I Hodgkin's disease: prognostic factors for survival and freedom from progression.
    Vlachaki MT; Hagemeister FB; Fuller LM; Besa PC; Hess MA; Brown B; Cabanillas F; Cox JD
    Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):593-9. PubMed ID: 9231684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved survival in patients with limited stage IIIA Hodgkin's disease treated with combined radiation therapy and chemotherapy.
    Marcus KC; Kalish LA; Coleman CN; Shulman LN; Rosenthal DS; Canellos GP; Mauch PM
    J Clin Oncol; 1994 Dec; 12(12):2567-72. PubMed ID: 7989930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic implications of mediastinal involvement in advanced Hodgkin's disease.
    Specht L; Nissen NI; Walbom-Jørgensen S
    Scand J Haematol; 1985 Aug; 35(2):166-73. PubMed ID: 3840275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy.
    Tubiana M; Henry-Amar M; Hayat M; Burgers M; Qasim M; Somers R; Sizoo W; van der Schueren E
    Int J Radiat Oncol Biol Phys; 1984 Feb; 10(2):197-210. PubMed ID: 6368491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of tumour burden in Hodgkin's disease PS I and II.
    Specht L; Nissen NI
    Scand J Haematol; 1986 Apr; 36(4):367-75. PubMed ID: 3754976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of long-term results and prognostic factors among 138 patients with advanced Hodgkin's disease treated with the alternating MOPP/ABVD chemotherapy.
    Brusamolino E; Orlandi E; Morra E; Castelli G; Pagnucco G; Livraghi A; Astori C; Santagostino A; Lazzarino M; Bernasconi C
    Ann Oncol; 1994; 5 Suppl 2():53-7. PubMed ID: 7515648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.
    Specht L; Nordentoft AM; Cold S; Clausen NT; Nissen NI
    Br J Cancer; 1987 May; 55(5):535-9. PubMed ID: 3300762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multivariate analysis of prognostic factors in adult Hodgkin's disease.
    Dienstbier Z; Chytrý P; Hermanská Z; Melínová L; Pĕnicka P; Maríková E
    Neoplasma; 1989; 36(4):447-56. PubMed ID: 2770931
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination.
    Specht L; Nissen NI
    Eur J Haematol; 1988 May; 40(5):396-402. PubMed ID: 3378595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose cyclophosphamide, carmustine, and etoposide with autologous transplantation in Hodgkin's disease: a prognostic model for treatment outcomes.
    Wheeler C; Eickhoff C; Elias A; Ibrahim J; Ayash L; McCauley M; Mauch P; Schwartz G; Eder JP; Mazanet R; Ferrara J; Rimm IJ; Guinan E; Bierer B; Gilliland G; Churchill WH; Ault K; Parsons S; Antman K; Schnipper L; Tepler I; Gaynes L; Frei E; Kadin M; Antin J
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):98-106. PubMed ID: 9267670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease.
    Fermé C; Eghbali H; Meerwaldt JH; Rieux C; Bosq J; Berger F; Girinsky T; Brice P; van't Veer MB; Walewski JA; Lederlin P; Tirelli U; Carde P; Van den Neste E; Gyan E; Monconduit M; Diviné M; Raemaekers JM; Salles G; Noordijk EM; Creemers GJ; Gabarre J; Hagenbeek A; Reman O; Blanc M; Thomas J; Vié B; Kluin-Nelemans JC; Viseu F; Baars JW; Poortmans P; Lugtenburg PJ; Carrie C; Jaubert J; Henry-Amar M;
    N Engl J Med; 2007 Nov; 357(19):1916-27. PubMed ID: 17989384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial.
    Hutchinson RJ; Fryer CJ; Davis PC; Nachman J; Krailo MD; O'Brien RT; Collins RD; Whalen T; Reardon D; Trigg ME; Gilchrist GS
    J Clin Oncol; 1998 Mar; 16(3):897-906. PubMed ID: 9508171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.